bioengineer.org /2 weeks ago

Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort

A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.

Read source
multiple-sclerosis-research.org /1 month ago

Frexalimab for progressive MS?

Here we go…Frexalimab to inhibit progressive MS?. Frexalimab is a CD40Ligand blocking antibody for development in MS. Frexalimab inhibits relapsing and progressive MS, so they say,...

Read source
hemophilianewstoday.com /5 days ago

New injection therapy for hemophilia A, Frehemgo, wins approval in Europe

The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union...

Read source
qchron.com /2 weeks ago

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) as First a...

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
cafepharma.com /2 weeks ago

Argenx

Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
cafepharma.com /1 month ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.